Literature DB >> 25190113

Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.

Harun Ilhan1, Wolfgang P Fendler, Clemens C Cyran, Christine Spitzweg, Christoph J Auernhammer, Franz-Josef Gildehaus, Peter Bartenstein, Martin K Angele, Alexander R Haug.   

Abstract

BACKGROUND: Resection is the only curative treatment in patients suffering from neuroendocrine tumors (NETs) of the ileum or the pancreas. Accurate preoperative imaging is critical for surgical planning, as even findings of small and distant metastases may profoundly influence surgical management.
METHODS: (68)Ga-DOTATATE PET/CT was performed preoperatively in 44 patients suffering from NET of the ileum (n = 26) or the pancreas (n = 18) before surgery at our University Hospital. Data were analyzed retrospectively by an interdisciplinary team of nuclear medicine and visceral surgery specialists. Intended surgical management was documented before and after availability of PET/CT findings. The team judged whether the imaging findings provided additional information relevant to surgical planning.
RESULTS: Imaging results altered surgical management in 9 of 44 (20 %) patients, more specifically in 3 of 26 (12 %) patients with NET of the ileum and in 6 of 18 (33 %) patients with NET of the pancreas. PET/CT findings led to a more invasive surgical approach in 6 cases (3 each of ileum and pancreas) and to a less invasive strategy in 3 patients with NET of the pancreas. Although PET/CT results did not alter management in 35 of 44 patients, somatostatin receptor imaging still provided additional information for surgery planning in more than 95 % of the cases.
CONCLUSIONS: Additional information provided by (68)Ga-DOTATATE PET/CT in the preoperative workup significantly influences surgical management in one-fifth of our NET patients and, notably, one-third of those suffering from NET of the pancreas.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25190113     DOI: 10.1245/s10434-014-3981-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  17 in total

1.  Pancreatic metastases from primary ileal NET only detected by 68Ga-DOTATOC PET/CT.

Authors:  P Mapelli; F Fallanca; A Franchini; L Albarello; E G Vanoli; S Partelli; F Muffatti; L Gianolli; M Falconi; M Picchio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-13       Impact factor: 9.236

Review 2.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

3.  The utility of 68Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors.

Authors:  Jasmine Shell; Amit Tirosh; Corina Millo; Samira M Sadowski; Yasmine Assadipour; Patience Green; Dhaval Patel; Naris Nilubol; Electron Kebebew
Journal:  Eur J Radiol       Date:  2018-11-22       Impact factor: 3.528

4.  Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Authors:  Samira M Sadowski; Vladimir Neychev; Corina Millo; Joanna Shih; Naris Nilubol; Peter Herscovitch; Karel Pacak; Stephen J Marx; Electron Kebebew
Journal:  J Clin Oncol       Date:  2015-12-28       Impact factor: 44.544

Review 5.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

Review 6.  Novel PET tracers: added value for endocrine disorders.

Authors:  Sébastien Bergeret; Judith Charbit; Catherine Ansquer; Géraldine Bera; Philippe Chanson; Charlotte Lussey-Lepoutre
Journal:  Endocrine       Date:  2019-03-14       Impact factor: 3.633

Review 7.  Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?

Authors:  Prasanna Santhanam; Sangeeta Chandramahanti; Alexander Kroiss; Run Yu; Philippe Ruszniewski; Rakesh Kumar; David Taïeb
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-13       Impact factor: 9.236

8.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

Review 9.  68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis.

Authors:  Stephen A Deppen; Jeffrey Blume; Adam J Bobbey; Chirayu Shah; Michael M Graham; Patricia Lee; Dominique Delbeke; Ronald C Walker
Journal:  J Nucl Med       Date:  2016-01-14       Impact factor: 10.057

Review 10.  Surgical Management of Neuroendocrine Tumor Liver Metastases.

Authors:  Catherine G Tran; Scott K Sherman; Chandrikha Chandrasekharan; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2020-10-20       Impact factor: 3.495

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.